Indevus Pharmaceuticals says that a late-stage study of Nebido--an injectable testosterone therapy for the treatment of male hypogonadism--met its primary endpoint, paving the way to a new drug application that will be filed later in the summer. The Lexington, MA-based company licensed the drug program from Bayer Schering Pharma.
"The market opportunity for Nebido is substantial," says Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The results of our trial demonstrate the potential of NEBIDO, the only once every three month treatment for male hypogonadism, to dramatically improve the treatment options for men who suffer from this condition."
- check out the release for more on the data
Indevus in $120M deal to acquire Valera. Report
Indevus halts research on pagoclone for PE. Report
Indevus shares rise on pagoclone data. Report
Indevus shares buoyed by new Sanctura data. Report